Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease

被引:18
作者
Basso, IN
Keeling, D [1 ]
机构
[1] Churchill Hosp, Oxford Haemophilia Ctr, Oxford OX3 7LJ, England
[2] Churchill Hosp, Thrombosis Unit, Oxford OX3 7LJ, England
关键词
myocardial infarction; recombinant activated factor VII;
D O I
10.1097/00001721-200408000-00010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We describe a 50-year-old man with von Willebrand disease type 2A who suffers from angiodysplasia and has required many transfusions for gastro-intestinal haemorrhage. Various investigative modalities have not demonstrated a single source for this. Following a case report of successful use of recombinant activated factor VII (NovoSeven(R); Novo Nordisk, Copenhagen, Denmark), the patient was treated with it but suffered a large myocardial infarct. As the patient has risk factors for atherosclerotic disease, we presume the recombinant activated factor VII promoted coagulation at a pre-existing atherosclerotic lesion.
引用
收藏
页码:503 / 504
页数:2
相关论文
共 9 条
[1]   Tissue-factor antigen and activity in human coronary atherosclerotic plaques [J].
Ardissino, D ;
Merlini, PA ;
Ariens, R ;
Coppola, R ;
Bramucci, E ;
Mannucci, PM .
LANCET, 1997, 349 (9054) :769-771
[2]   Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors [J].
Hough, RE ;
Hampton, KK ;
Preston, FE ;
Channer, KS ;
West, J ;
Makris, M .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (03) :974-979
[3]   Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa [J].
Meijer, K ;
Peters, FTM ;
van der Meer, J .
BLOOD COAGULATION & FIBRINOLYSIS, 2001, 12 (03) :211-213
[4]   Use of recombinant factor VIIa (NovoSeven®) in patients with Glanzmann thrombasthenia [J].
Poon, MC ;
d'Oiron, R ;
Hann, I ;
Négrier, C ;
de Lumley, L ;
Thomas, A ;
Karafoulidou, A ;
Demers, C ;
Street, A ;
Huth-Kühne, A ;
Petrini, P ;
Fressinaud, E ;
Morfini, M ;
Tengborn, L ;
Marquès-Verdier, A ;
Musso, R ;
Devecioglu, O ;
Houston, DS ;
Lethagen, S ;
Van Geet, C ;
von Depka, M ;
Berger, C ;
Beurrier, P ;
Britton, HA ;
Gerrits, W ;
Guthner, C ;
Kuhle, S ;
Lorenzo, JJ ;
Makris, PE ;
Nohe, N ;
Paugy, P ;
Pautard, B ;
Torchet, MF ;
Trillot, N ;
Vicariot, M ;
Wilde, J ;
Winter, M ;
Chambost, H ;
Ingerslev, J ;
Peters, M ;
Strauss, G .
SEMINARS IN HEMATOLOGY, 2001, 38 (04) :21-25
[5]   Safety profile of recombinant factor VIIa [J].
Roberts, HR ;
Monroe, DM ;
Hoffman, M .
SEMINARS IN HEMATOLOGY, 2004, 41 (01) :101-108
[6]   Clinical liver transplantation [J].
Roberts, J .
AMERICAN JOURNAL OF TRANSPLANTATION, 2001, 1 (01) :18-20
[7]   MORTALITY AND CAUSES OF DEATH IN DUTCH HEMOPHILIACS, 1973-86 [J].
ROSENDAAL, FR ;
VAREKAMP, I ;
SMIT, C ;
BROCKERVRIENDS, AHJT ;
VANDIJCK, H ;
VANDENBROUCKE, JP ;
HERMANS, J ;
SUURMEIJER, TPBM ;
BRIET, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1989, 71 (01) :71-76
[8]  
SULLIVAN DW, 1984, PEDIATRICS, V74, P279
[9]  
Tengborn L, 1996, THROMB HAEMOSTASIS, V75, P981